TH64346A - Pharmacological components in the treatment of tissue damage due to aortic circulatory failure. - Google Patents

Abstract

DC60 This invention concerns a human drug, specifically a pharmaceutical complex composed of epidermal growth factor (EGF) and growth hormone secretion-stimulating hexapeptide (GHRP); for use in preventing tissue damage due to circulatory depression and in enhancing tissue repair after ischemic damage. The aforementioned complex may be used as individual pharmaceutical components, or alternatively, both EGF and GHRP may be administered separately as a single therapeutic regimen to enhance cell survival during critical periods of organ ischemia. This complex reduces the generation of reactive oxygen species (ROS) and their associated cytotoxicity. This complex is beneficial in promoting cell survival when tissue is affected. Or, in cases where organs are exposed to prolonged periods of ischemia, the combination may be used as a preventative measure in individuals prone to multiple organ failure (MOF), such as burn patients, patients with multiple wounds, oxygen-deprived newborns, acute respiratory syndrome, and patients with colitis leading to tissue or cell death. This invention concerns a human drug, specifically one involving a pharmacological combination of Epidermal Growth Factor (EGF) and Growth Hormone Sclerogehoxapertide (GHRP) to prevent tissue damage due to circulatory depression and to enhance tissue repair after damage from ischemia. The combination may be used as a single pharmacological mixture; alternatively, patients may receive both EGF and GHRP separately in a single treatment regimen to enhance cell survival when organs experience a critical period of ischemia. This mixture reduces the generation of reactive oxygen species (ROS) and their associated cytotoxicity. It is beneficial in supporting cell survival when tissues or organs are exposed to prolonged periods of ischemia. The mixture may be used as a preventative measure in individuals prone to multiple organ failure (MOF), such as burn patients, patients with multiple wounds, oxygen-deprived newborns, acute respiratory infections, and patients with colitis leading to tissue or cell death.

Claims (19)

1. A pharmaceutical compound characterized by the administration of a peptide containing the active epidermal growth factor (EPTF) combined with a growth hormone-stimulating hexapeptide (GHRP-6) for the prevention and treatment of tissue damage due to aortic ischemia and its consequences in animals and humans. 2. A pharmaceutical mixture pursuant to claim 1, in which an epidermal growth factor-active peptide can be epidermal growth factor (EGF), transforming growth factor type alpha (TGF-alpha), or heparin-binding EGF-like growth factor (HB-EGF). 3. The pharmaceutical mixture pursuant to claim 1, in which the epidermal growth factor-active peptide and the growth hormone-stimulating hexapeptide GHRP-6 are components of the single pharmaceutical mixture with appropriate additional explorers. 4. A pharmaceutical compound pursuant to claim 1, which delivers a hexapeptide that stimulates the secretion of growth hormone GHRP-6 alone or in combination with an epidermal growth factor-active peptide to a patient as part of prevention or treatment. 5. A pharmaceutical mixture pursuant to any one of claims 1 through 4, in which a peptite exhibits epidermal growth factor activity at concentrations of 0.5–50 µg/ml when prepared as a solution or as an iophyllide. 6. Any pharmaceutical mixture under claims 1 through 4 in which the growth hormone-stimulating hexapeptide GHRP-6 is present at a concentration of 2 y 100 mcg/ml when prepared as a solution or as a lyophilized form. 7. Any pharmaceutical mixture as per claims 1 through 6, which must be administered non-intestinally in a single large dose (bolnus) to achieve prophylactic activity in the range of 0.5–1 µg of each active peptide per kg body weight. 8. A pharmaceutical mixture pursuant to any one of claims 1 through 6, which must be administered intravenously on a sustained flow basis to induce metabolizing/regenerating effects at a dose of 0.01 to 5 mcg of each active peptide per kilogram of patient body weight. 9. Pharmaceutical mixtures characterized by the presence of a hexapeptide that stimulates the secretion of growth hormone (GHRP-6) and an exypient suitable for inducing protection against ischemic damage in order to prevent tissue damage when there is erosion of the aorta in humans and animals. 10. The use of any pharmaceutical combination under claims 1 through 8 to prevent tissue damage, whether serious or not, to the affected tissue/organ by non-returning blood shortage, effluent conditions, or lack of blood/fluid replacement. 11. The use of any one of the pharmaceutical combinations under claims 1 through 8 for the relief or as an adjuvant treatment of adult respiratory distress (ARDS). 12. The use of pharmaceutical combinations as per claims 1 through 8 for the prevention and treatment of multiple organ dysfunction syndrome and related procedures requiring intensive care. 13. Use of pharmaceutical combinations under claim 12 in the treatment of patients with burn wounds, multiple traumas, extensive surgery, transplants, reconstructive surgery, cardiovascular devices, thrombolytic and/or fibrinolytic therapy and circulatory restoration, crush syndromes, ischemic patients, shock, and low cardiac output. 14. The use of any one of the pharmaceutical combinations under claims 1 through 8 as an adjuvant therapy for bleeding, fluid redistribution disorders, shock, and anemia/visual fluid redistribution. 15. The use of any one of the pharmaceutical mixtures under claims 1 through 8 as a preventative and pre-operative agent for transplantation surgery; prolonged blood shortage resulting from surgery; and any other condition that gives rise to the onset of visceral organ ischemia, systemic inflammatory disease, and multi-organ dysfunction. 16. The use of pharmaceutical mixtures as per claim 15 in maintaining the homeostasis of the internal environment of organs and tissues during vascular or tubular reconstruction surgery and in enhancing the survival of any transplants after organ transplantation such as kidney, liver, pancreas, intestine, lung, heart and skin grafts. 17. The use of any pharmaceutical combination under claims 1 through 8 to prevent any type of cell damage after any condition which can obstruct the passage of oxygenated blood fluid into tissues. 18. The use of a pharmaceutical combination pursuant to any one of claims 1 through 8 in the treatment of functional coordination of tissue/organ after a case resulting in tissue or cell death. 19. The use of pharmaceutical combinations under claims 1 through 8 to stimulate intestinal adaptation processes following partial bowel resection, short bowel syndrome, bowel failure, etc., with or without association with total parpenteran nutrition.